NCT03202316: Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have confirmed diagnosis of inflammatory breast cancer 
Exclusions: Unstable, symptomatic or untreated brain metastasis and/or CNS metastases
https://ClinicalTrials.gov/show/NCT03202316

Comments are closed.

Up ↑